Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

o had not responded to previous interferon-based treatment regimens.

"The final Phase 2b results suggest that the every-two-week dosing regimen of Albuferon halves the number of injections that are required with peginterferon alfa-2a, while providing at least comparable efficacy, comparable safety and the potential for less impairment of quality of life and daily activity," said Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany. "We are continuing the evaluation of the 900-mcg and 1200-mcg doses of Albuferon in larger populations in Phase 3 trials. We also conclude that monthly dosing of Albuferon deserves further evaluation."

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with genotype 1 chronic hepatitis C were randomized to four treatment groups: Albuferon 900 mcg every two weeks, Albuferon 1200 mcg every two weeks, Albuferon 1200 mcg every four weeks, and peginterferon alfa-2a 180 mcg once a week. All patients received weight-based oral ribavirin daily. The trial included 48 weeks of treatment, and the primary efficacy endpoint was SVR, defined as undetectable viral load (HCV RNA<10 IU/mL) at 24 weeks following completion of treatment.

"Assuming that the Phase 2 results are confirmed in Phase 3, we believe that Albuferon could become the interferon of choice in combination regimens for the treatment of chronic hepatitis C," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Both of our Phase 3 trials have completed enrollment ahead of schedule, and we expect to have Phase 3 data available by spring 2009 to support the filing of global marketing authorization applications by fall 2009."

Key Findings from the Phase 2b Study

Albuferon requires half the number of injections as peginterferon alfa-2a, and the final results of the Phase 2b study demonstrated that Albuferon provid
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... /PRNewswire-iReach/ -- TwinMed, LLC announced today that ... H.Eric Richard, Inc. (collectively "PrimeCare"), a New England based ... Massachusetts and Maine. "This acquisition is ... substantially increase our base of service for Long Term ...
... flu season still active and allergy season on its ... to actively seek their pharmacist,s advice about the proper ... care provider and are available to help the public ... and allergy symptoms. (Logo: http://photos.prnewswire.com/prnh/20100820/APHALOGO-a ) ...
Cached Medicine Technology:Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... Aug. 19 Lupin Ltd.,announced today that the Company ... the AeroChamber Plus(R) line of products with,Forest Laboratories, Inc. ... will use its 50 person sales force to promote,the ... Holding Chamber (VHC) device that is,used with metered dose ...
... Private Access Appoints Marc Kirshbaum as President & COO, Former ... Medical Research through its suite of web-based privacy management ... clinical ... Private Access,Inc., a developer of web-based solutions that enable management ...
... LINTHICUM, MD, August 18, 2008Young researchers presented innovative, ... Conference, a collaborative project of the AUA Foundation ... on August 7-9, 2008. The AUA Foundation hosted ... discuss the most cutting-edge research in sexual medicine. ...
... Team Conference on October 23,2008, ALEXANDRIA, Va., ... improving America,s future. A strong advocate for,children and ... advocate and,tireless worker on behalf of important social ... Edwards will be the opening speaker at,the National ...
... Cialis showed benefit without side effects , , TUESDAY, ... the erectile dysfunction drug tadalafil (Cialis) helped relieve lower ... prostates, according to a new study. , More than ... lower urinary tract symptoms, including increased urination frequency and ...
... more wide-spread ... authentication for network access, DALLAS, Aug. 19 To ... two-factor authentication via hardware tokens in order to,protect patient files, ... to deploy to a wider audience and,cumbersome for the medical ...
Cached Medicine News:Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2Health News:Elizabeth Edwards to be Opening Speaker at National Hospice Conference in Dallas 2Health News:ED Drug Relieves Lower Urinary Tract Symptoms 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 3
... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
Inquire...
Medicine Products: